Slides
Page 1
SUZUKEN CO . , LTD . [ Stock Code : 9987 ] S SUZUKEN Financial Results Briefing 1Q Period Ended June 30 , 2026 $ August 7 , 2026
Page 2
© 2026 SUZUKEN CO., LTD. 2 Table of Contents 1Q Period Ended June 30, 2026 1. Consolidated Results P.3 2. Pharmaceutical Distribution P.4 3. Digital P.5 4. Logistics P.6 5. Healthcare Product Development P.7 6. Community Healthcare and Nursing Care Support P.8 7. Other Operations P.9 Reference: Companies Included in Each Segment P.10
Page 3
© 2026 SUZUKEN CO., LTD. 3 1Q Period Ended June 30, 2026 1Q Period Ended June 30, 2025 Results Year-on-year Change Year-on-year Growth Rate Results Net sales 628,962 36,089 6.1 592,872 Gross profit 43,349 83 0.2 43,266 (Ratio to net sales) 6.89 7.30 SG&A 39,158 1,479 3.9 37,679 (Ratio to net sales) 6.23 6.36 Operating profit 4,190 (1,396) (25.0) 5,586 (Ratio to net sales) 0.67 0.94 Ordinary profit 5,074 (709) (12.3) 5,783 (Ratio to net sales) 0.81 0.98 Profit attributable to owners of parent 3,381 (400) (10.6) 3,782 (Ratio to net sales) 0.54 0.64 ⚫ Net sales increased due to growth in the prescription drug market, supported by strong sales of new drugs, primarily specialty drugs. At present, sales prices have not yet been finalized for slightly less than 90% of our customers across the group. For those customers, revenue has been estimated based on the pricing levels requested by each customer. ⚫ Operating profit decreased due to rising procurement costs for pharmaceuticals and other items, as well as inflation-driven increases in operating expenses, including higher outsourcing costs. Upfront digital-related investments for growth and increased research and development expenses also contributed to the decline. Consolidated Results (Millions of yen, %) 1Q Period Ended June 30, 2026
Page 4
© 2026 SUZUKEN CO., LTD. 4 1Q Period Ended June 30, 2026 1Q Period Ended June 30, 2025 Results Year-on-year Change Year-on-year Growth Rate Results Net sales 607,825 36,214 6.3 571,610 Gross profit 31,456 540 1.7 30,916 (Ratio to net sales) 5.18 5.41 SG&A 27,928 977 3.6 26,951 (Ratio to net sales) 4.59 4.71 Operating profit 3,528 (436) (11.0) 3,965 (Ratio to net sales) 0.58 0.69 Ordinary profit 4,754 (949) (16.6) 5,703 (Ratio to net sales) 0.78 1.00 FY2026 1Q Market SZ Diff. Based on drug price (IQVIA) 4.1 5.1 1.0 Based on delivery price (Crecon) 5.2 6.8 1.6 ◇ Market growth and sales growth rate of SZ Group FY2026 1Q FY2025 1Q In value terms 10.6％ 10.6% ◇ Price settlement rate ⚫ Net sales increased due to growth in the prescription drug market, supported by strong sales of new drugs, primarily specialty drugs (specialty drug distribution client companies: 41; contracted products: 83; up 1 client and 2 products YoY). ⚫ Operating profit decreased due to the continued rise in procurement costs for pharmaceuticals and other items, as well as inflation-driven increases in operating expenses, including higher outsourcing costs, despite initiatives to establish appropriate price formation in accordance with the Guidelines for the Improvement of Commercial Transaction Practices and efforts to review and control selling, general and administrative expenses. Specialty drugs 134,407 35,545 36.0 98,862 1Q Period Ended June 30, 2026 Pharmaceutical Distribution (Millions of yen, %) <Net sales>
Page 5
© 2026 SUZUKEN CO., LTD. 5 1Q Period Ended June 30, 2026 1Q Period Ended June 30, 2025 Results Year-on-year Change Year-on-year Growth Rate Results Net sales 808 202 33.4 606 Gross profit 180 68 61.3 112 (Ratio to net sales) 22.34 18.47 SG&A 510 353 224.5 157 (Ratio to net sales) 63.09 25.93 Operating profit (329) (284) ー (45) (Ratio to net sales) (40.75) (7.46) Ordinary profit (335) (281) ー (53) (Ratio to net sales) (41.43) (8.82) ⚫ Net sales increased, driven by promotion revenue related to AI-MS at Collabo Square. ⚫ Operating loss was recorded due primarily to an increase in selling, general and administrative expenses associated with upfront investments, including hiring personnel for new service development and business foundation enhancement. 1Q Period Ended June 30, 2026 Digital (Millions of yen, %) <medimo> • Strengthening the promotion framework through eight regional blocks, tailored to local characteristics <COLLABO Portal> • Strengthening ID integration initiatives, including Medshiru AI (Nankodo) <Cubixx> • Developed and launched “Cubixx Link,” a system that ensures traceability during in-hospital transport *News release disclosed on July 9, 2026 (LINK)
Page 6
© 2026 SUZUKEN CO., LTD. 6 1Q Period Ended June 30, 2026 1Q Period Ended June 30, 2025 Results Year-on-year Change Year-on-year Growth Rate Results Net sales 14,476 413 2.9 14,062 Gross profit 1,509 235 18.5 1,273 (Ratio to net sales) 10.42 9.06 SG&A 565 48 9.3 517 (Ratio to net sales) 3.91 3.68 Operating profit 943 187 24.7 756 (Ratio to net sales) 6.51 5.38 Ordinary profit 959 223 30.5 735 (Ratio to net sales) 6.62 5.23 ⚫ Net sales increased, driven by the revision of contract pricing in the wholesale logistics business and higher distribution volumes in the contract logistics services for pharmaceutical manufacturers (“Manufacturer Logistics”). (Manufacturer Logistics client companies: 47, unchanged YoY). ⚫ Operating profit also increased as a result of continued efforts to improve productivity, despite the escalation of various costs. 1Q Period Ended June 30, 2026 Logistics (Millions of yen, %)
Page 7
© 2026 SUZUKEN CO., LTD. 7 1Q Period Ended June 30, 2026 1Q Period Ended June 30, 2025 Results Year-on-year Change Year-on-year Growth Rate Results Net sales 12,934 271 2.1 12,663 Gross profit 4,010 (180) (4.3) 4,190 (Ratio to net sales) 31.00 33.09 SG&A 3,718 380 11.4 3,337 (Ratio to net sales) 28.75 26.35 Operating profit 292 (561) (65.8) 853 (Ratio to net sales) 2.26 6.74 Ordinary profit 298 (572) (65.8) 870 (Ratio to net sales) 2.30 6.87 ⚫ Net sales increased despite the impact of drug price revisions, driven by growth in sales of UPASITA IV Injection Syringe for Dialysis and Darbepoetin Alfa BS Syringe for Injection within the pharmaceutical manufacturing division, as well as solid performance in the medical equipment and materials manufacturing division. ⚫ Operating profit decreased due to a decline in the gross profit margin resulting from factors such as drug price revisions, as well as an increase in research and development expenses associated with the progress in the development of Paltusotine. Pharmaceutical Manufacturing 11,700 241 2.1 11,459 Medical Equipment and Materials Manufacturing 1,233 30 2.5 1,203 1Q Period Ended June 30, 2026 Healthcare Product Development (Millions of yen, %) <Net sales>
Page 8
© 2026 SUZUKEN CO., LTD. 8 1Q Period Ended June 30, 2026 1Q Period Ended June 30, 2025 Results Year-on-year Change Year-on-year Growth Rate Results Net sales 22,719 (397) (1.7) 23,116 Gross profit 7,626 (428) (5.3) 8,054 (Ratio to net sales) 33.57 34.84 SG&A 7,855 (176) (2.2) 8,031 (Ratio to net sales) 34.58 34.74 Operating profit (229) (251) 22 (Ratio to net sales) (1.01) 0.10 Ordinary profit (68) (133) 64 (Ratio to net sales) (0.30) 0.28 Pharmacy 20,041 (464) (2.3) 20,505 Nursing Care 2,654 62 2.4 2,591 Medical and Nursing Care Support 23 3 18.6 19 1Q Period Ended June 30, 2026 Community Healthcare and Nursing Care Support ⚫ In the pharmacy division, although the average drug cost and dispensing fee revenue per prescription increased, driven by a higher number of prescriptions for high-cost pharmaceuticals and wider adoption of medical DX-related reimbursement add-ons, revenue declined due to a decrease in the number of prescriptions processed. This reflected both fewer prescription visits associatedwith longer prescription durations and a reduction in the number of operating pharmacy stores following closures (group pharmacy stores: 505, down 23 stores YoY). ⚫ In the nursing care division, net sales increased, supported by an improvement in the occupancy rate at existing facilities and an increase in the number of users. ⚫ Operating loss was recorded due to a decrease in gross profit resulting from lower revenue, despite efforts to control selling, general and administrative expenses. (Millions of yen, %) <Net sales>
Page 9
© 2026 SUZUKEN CO., LTD. 9 1Q Period Ended June 30, 2026 1Q Period Ended June 30, 2025 Results Year-on-year Change Year-on-year Growth Rate Results Net sales 1,363 (30) (2.2) 1,393 Gross profit 481 5 1.1 476 (Ratio to net sales) 35.32 34.20 SG&A 459 22 5.0 437 (Ratio to net sales) 33.69 31.38 Operating profit 22 (16) (43.2) 39 (Ratio to net sales) 1.64 2.82 Ordinary profit 22 (34) (61.3) 56 (Ratio to net sales) 1.61 4.08 1Q Period Ended June 30, 2026 Other Operations ⚫ Net sales decreased due to factors including a decline in the equipment procurement business. ⚫ Operating profit decreased due to lower sales revenue. (Millions of yen, %)
Page 10
© 2026 SUZUKEN CO., LTD. 10 New Segment Main Companies Pharmaceutical Distribution *including Specialty Drug Contract Distribution business Suzuken, Sanki, ASTIS, Shoyaku, Suzuken Okinawa Yakuhin, Nakano Yakuhin, Suzuken Iwate, S.D. Collabo Digital *NEW Collabo Square, medimo Logistics *NEW Collabo CREATE S.D.Logi, CHUOUNYU Healthcare Product Development (Pharmaceutical manufacturing) Sanwa Kagaku Kenkyusho (Medical equipment and materials manufacturing) Kenzmedico Community Healthcare and Nursing Care Support (Pharmacy) UNISMILE (Nursing care) Sanki Wellbe, S-Care Mate (Medical and nursing care support) Medicare Collabo Other Operations Life Support Previous Segment Main Companies Pharmaceutical Distribution Suzuken, Sanki, ASTIS, Shoyaku, Suzuken Okinawa Yakuhin, Nakano Yakuhin, Suzuken Iwate, S.D.Logi Healthcare Product Development (Pharmaceutical manufacturing) Sanwa Kagaku Kenkyusho (Medical equipment and materials manufacturing) Kenzmedico Community Healthcare and Nursing Care Support (Pharmacy) UNISMILE (Nursing care) Sanki Wellbe, S-Care Mate (Medical and nursing care support) Medicare Collabo Specialty Drug Contract Distribution S.D. Collabo Healthcare-Related Services （External logistics） CHUOUNYU, S.D. Collabo *Effective April 1, 2026, the Manufacturer Logistics business was transferred to Collabo CREATEthrough a company split （Other） Collabo Square 1Q Period Ended June 30, 2026 Reference: Companies Included in Each Segment
Page 11
This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. Information disclosed by Suzuken may include matters related to future forecasts. These matters are based on management decisions pursuant to the information available to the company at the time of disclosure, and utilize certain assumptions in order to create future forecasts. They contain a variety of risks and uncertainties. As a result, the actual performance figures, results, and other matters may differ from the forecasts contained in disclosed information due to various future factors such as changes in business operations and the economic situation.